Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin

Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data Release HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced a significant advancement in its intellectual property portfolio with the issuance of a Hong Kong patent covering its proprietary method of reconstituting liposomal Annamycin. The newly granted patent (No.